- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Childhood Sexual Abuse Litigation
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Restructuring and Business Bankruptcy
- Wealth Planning, Administration, and Disputes
- Litigation Support Services
-
November 18, 2019Robins Kaplan LLP Announces Launch of Newly Designed Website
-
October 22, 2019Boston Attorneys Recognized as 2019 Super Lawyers and Rising Stars
-
October 22, 2019Two Partners Named Finalists for the Los Angeles Business Journal Leaders in Law Award
-
November 20-21, 2019Edge AI Summit
-
November 20, 2019Minnesota High Tech Association Tekne Awards
-
November 21, 2019Minneapolis 1L Diversity Clerkship and Summer Associate Opportunities Reception
-
August 29, 2019Allergan Sales, LLC v. Sandoz, Inc
-
September 19, 2019Amgen Inc. v. Amneal Pharms. LLC
-
Fall 2019ANDA Approvals
Find additional firm contact information for press inquiries.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generics Need Sword, Shield For 'Exceptional' Patent Case
Strategies for generic drug companies to avoid paying exceptional-case attorney fees and costs in patent litigation with brand holder.
September 18, 2014
Generic drug companies marketing in the U.S. have particularly rough going these days. The year 2013 saw substantial new Generic Drug User Fee Amendments "user fees" levied on generics for access to the U.S.Food and Drug Administration. The same year brought the U.S. Supreme Court’s Actavis decision: Now the Federal Trade Commission can sue generics for structuring pharma litigation settlements such that the generic company receives something of value from the brand.
All Content © 2003‐2014, Portfolio Media, Inc.
The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.
Law360
READ FULL ARTICLE Related Professionals
Jeffrey Alan Hovden
Partner
Related Publications
August 29, 2019
Allergan Sales, LLC v. Sandoz, Inc
GENERICally Speaking Fall 2019
September 19, 2019
Amgen Inc. v. Amneal Pharms. LLC
GENERICally Speaking Fall 2019
Fall 2019
ANDA Approvals
GENERICally Speaking Fall 2019
Fall 2019
ANDA Litigation Settlements
GENERICally Speaking Fall 2019
July 17, 2019
Bausch Health Cos. v. Actavis Labs. FL
GENERICally Speaking Fall 2019
Related News
September 16, 2019
July 26, 2019
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.